Comparative Pharmacology
Head-to-head clinical analysis: RONDOMYCIN versus TETREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RONDOMYCIN versus TETREX.
RONDOMYCIN vs TETREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
150 mg orally twice daily or 300 mg orally once daily.
250-500 mg orally every 6 hours or 500 mg to 1 g intravenously every 6-12 hours, not to exceed 4 g/day.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in patients with normal renal function; may extend to 20-30 hours in severe renal impairment.
Terminal elimination half-life: 6-11 hours (mean 8 hours); prolonged in renal impairment (up to 20 hours).
Renal (40-50% unchanged), biliary/fecal (10-20% as metabolites and unchanged drug). Approximately 30% undergoes enterohepatic circulation.
Renal: 60% unchanged; biliary/fecal: 40% (mainly as glucuronide conjugates).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic